Post-finasteride syndrome: our current knowledge
5-α reductase inhibitors are effective and commonly used medications for the treatment of benign prostatic hyperplasia. However, there are some questions about the safety of such medications. A post-finasteride syndrome is a controversial syndrome associated with a constellation of sexual, physical,...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
State Budget Educational Institute of Higher Professional Education, Rostov State Medical University, Ministry Health of Russian Federation
2020-07-01
|
| Series: | Vestnik Urologii |
| Subjects: | |
| Online Access: | https://www.urovest.ru/jour/article/view/330 |
| _version_ | 1797272159948636160 |
|---|---|
| author | A. A. Galushkin D. G. Likhikh M. I. Kogan |
| author_facet | A. A. Galushkin D. G. Likhikh M. I. Kogan |
| author_sort | A. A. Galushkin |
| collection | DOAJ |
| description | 5-α reductase inhibitors are effective and commonly used medications for the treatment of benign prostatic hyperplasia. However, there are some questions about the safety of such medications. A post-finasteride syndrome is a controversial syndrome associated with a constellation of sexual, physical, and psychological symptoms that develop during or after finasteride exposure and persist after discontinuation. Finasteride and dutasteride have the same mechanism of action and we can suppose that the term «post-finasteride syndrome» may apply to the whole group of 5-alfa reductase inhibitors. Nowadays, reasons and development mechanisms of this syndrome are unclear. The results of studies on sexual, physical, and psychological disorders have shown mixed results. Some experts attribute post-finasteride syndrome to a group of «mysterious diseases» based on psychosocial factors. Also, we need new studies with better design because reasons and development mechanisms of this syndrome are unclear.Aleksandr A. Galushkin and Dmitriу G. Likhikh are employees GlaxoSmithKline Trading, Michael I. Kogan declares no conflict of interest. |
| first_indexed | 2024-03-07T14:24:22Z |
| format | Article |
| id | doaj.art-8666079755204ee99cef6d29d513d21c |
| institution | Directory Open Access Journal |
| issn | 2308-6424 |
| language | Russian |
| last_indexed | 2024-03-07T14:24:22Z |
| publishDate | 2020-07-01 |
| publisher | State Budget Educational Institute of Higher Professional Education, Rostov State Medical University, Ministry Health of Russian Federation |
| record_format | Article |
| series | Vestnik Urologii |
| spelling | doaj.art-8666079755204ee99cef6d29d513d21c2024-03-06T08:56:04ZrusState Budget Educational Institute of Higher Professional Education, Rostov State Medical University, Ministry Health of Russian FederationVestnik Urologii2308-64242020-07-0182505410.21886/2308-6424-2020-8-2-50-54244Post-finasteride syndrome: our current knowledgeA. A. Galushkin0D. G. Likhikh1M. I. Kogan2GlaxoSmithKline TradingGlaxoSmithKline TradingRostov State Medical University5-α reductase inhibitors are effective and commonly used medications for the treatment of benign prostatic hyperplasia. However, there are some questions about the safety of such medications. A post-finasteride syndrome is a controversial syndrome associated with a constellation of sexual, physical, and psychological symptoms that develop during or after finasteride exposure and persist after discontinuation. Finasteride and dutasteride have the same mechanism of action and we can suppose that the term «post-finasteride syndrome» may apply to the whole group of 5-alfa reductase inhibitors. Nowadays, reasons and development mechanisms of this syndrome are unclear. The results of studies on sexual, physical, and psychological disorders have shown mixed results. Some experts attribute post-finasteride syndrome to a group of «mysterious diseases» based on psychosocial factors. Also, we need new studies with better design because reasons and development mechanisms of this syndrome are unclear.Aleksandr A. Galushkin and Dmitriу G. Likhikh are employees GlaxoSmithKline Trading, Michael I. Kogan declares no conflict of interest.https://www.urovest.ru/jour/article/view/330post-finasteride syndrome5-alfa reductase inhibitorspsychological disordersmetabolic disorderssexual dysfunction |
| spellingShingle | A. A. Galushkin D. G. Likhikh M. I. Kogan Post-finasteride syndrome: our current knowledge Vestnik Urologii post-finasteride syndrome 5-alfa reductase inhibitors psychological disorders metabolic disorders sexual dysfunction |
| title | Post-finasteride syndrome: our current knowledge |
| title_full | Post-finasteride syndrome: our current knowledge |
| title_fullStr | Post-finasteride syndrome: our current knowledge |
| title_full_unstemmed | Post-finasteride syndrome: our current knowledge |
| title_short | Post-finasteride syndrome: our current knowledge |
| title_sort | post finasteride syndrome our current knowledge |
| topic | post-finasteride syndrome 5-alfa reductase inhibitors psychological disorders metabolic disorders sexual dysfunction |
| url | https://www.urovest.ru/jour/article/view/330 |
| work_keys_str_mv | AT aagalushkin postfinasteridesyndromeourcurrentknowledge AT dglikhikh postfinasteridesyndromeourcurrentknowledge AT mikogan postfinasteridesyndromeourcurrentknowledge |